Todas las investigaciones
Activo, no reclutandoFASE1, FASE2INTERVENCIONISTA

Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis

This research is looking at a new treatment called PBGM01 for a rare genetic condition called GM1 gangliosidosis, specifically in young children aged between 1 month and 2 years. GM1 gangliosidosis affects how the body breaks down certain substances, leading to serious health problems. PBGM01 is a 'gene therapy' which means it tries to give the body a working copy of a missing gene (called GLB1). The main goals of this study are to find out if PBGM01 is safe, how well people tolerate it, and if it helps improve the condition. The study will happen in two parts, first finding the right dose, and then testing its effects more widely.

De un vistazo

Estado
Activo, no reclutando
Fase
FASE1, FASE2
Patrocinador
Gemma Biotherapeutics
Objetivo de inscripción
26
Inicio
17 Mar 2021
Estimación de finalización
01 Feb 2029

¿De qué trata este estudio?

This study is about a new treatment for a rare and serious genetic condition called GM1 gangliosidosis. In simple terms, children with this condition are missing a vital enzyme (a type of protein that helps the body do its job) called beta-galactosidase. Without this enzyme, harmful substances build up in the body, especially in the brain, causing a range of health problems from early childhood.

The new treatment, called PBGM01, is a type of 'gene therapy'. Imagine your body's cells are like tiny factories, and the GLB1 gene is a blueprint for making the important beta-galactosidase enzyme. In GM1 gangliosidosis, this blueprint is faulty or missing. PBGM01 aims to deliver a correct, working copy of the GLB1 gene into the body's cells. The hope is that with this new blueprint, the cells can start making the missing enzyme, which could help reduce the build-up of harmful substances and improve the children's health. The treatment is given as a single injection into an area near the brain.

This study is designed in two main parts. The first part will carefully test different amounts (doses) of PBGM01 to find the safest and most suitable dose for children with type 1 and type 2a GM1 gangliosidosis. Once the best dose is found, the second part of the study will involve more children to further check how safe and effective the treatment is over time. The study will last for two years, with an additional three years of safety checks afterward.

Puntos clave

  • This study is for children with GM1 gangliosidosis (types 1 and 2a).
  • It tests a new gene therapy called PBGM01.
  • The therapy aims to replace a missing gene to help the body make an important enzyme.
  • The study checks for safety, how well it's tolerated, and if it helps symptoms.
  • It involves a single injection of the treatment.
  • Participation could last up to five years with regular check-ups.

¿Quién puede ser elegible?

To be considered for this study, your child must have a confirmed diagnosis of GM1 gangliosidosis, meaning genetic tests show changes in both copies of the GLB1 gene and laboratory tests confirm a lack of the important beta-galactosidase enzyme.

For children with Type 1 GM1 gangliosidosis: They must be between 1 month and under 12 months old when they join the study. They should also have shown the first signs of GM1 before 6 months of age and still meet certain development milestones.

For children with Type 2a GM1 gangliosidosis: They must be between 6 months and 24 months old when they join. Their first signs of GM1 should have appeared between 6 and 18 months of age, and they must be able to sit up by themselves for at least 10 seconds without help.

Children may not be able to participate if they have other significant brain or thinking problems not related to GM1, have been very unwell and needed to stay in hospital recently, or need help breathing with a machine (like a ventilator or tracheostomy). Children who have had severe, uncontrolled seizures (like status epilepticus) or seizures requiring a hospital visit within the last 30 days also cannot join. However, children who use special vests for breathing or a breathing machine for sleep apnea for less than 12 hours a day might still be eligible.

¿Podría este estudio ser adecuado para ti?

Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.

  1. Does your child have a confirmed GM1 gangliosidosis diagnosis with genetic and enzyme test results?
  2. If Type 1: Is your child between 1 and 12 months old and showed first signs before 6 months with certain basic development remaining?
  3. If Type 2a: Is your child between 6 and 24 months old, showed first signs between 6 and 18 months, and can sit unassisted for 10 seconds?
  4. Has your child had any serious brain problems not caused by GM1?
  5. Has your child needed breathing support (like a ventilator) for their condition?
  6. Has your child had severe, uncontrolled seizures recently (within the last month)?
Responde cada pregunta para ver tu resultado.

¿En qué consiste la participación?

If your child takes part in this study, they will receive a single dose of the study drug, PBGM01, given as an injection near the brain. The first part of the study will involve different groups of children receiving varying doses to determine the best amount. Over the next two years, your child will have regular visits to the study clinic. During these visits, doctors and nurses will closely monitor your child's health, do physical examinations, take blood samples, and perform other tests to check for any side effects and see how the treatment is working. This might include assessments of their development and other body functions. After the initial two years, there will be a further three years where your child's safety and health will continue to be monitored, though visits might be less frequent. This means the total commitment to the study could be up to five years.

Riesgos y beneficios potenciales

Taking part in any clinical trial involves potential benefits and risks. For your child, a potential benefit of this study could be that PBGM01 might help their body produce the missing enzyme, possibly slowing down or improving the symptoms of GM1 gangliosidosis. However, this is a new treatment, and it's not guaranteed to work, or the benefits might not be long-lasting. Potential risks could include side effects from the treatment itself, or from the procedures involved in monitoring your child's health. While doctors will monitor your child very closely, there might be unknown risks. It's very important to remember that participating is entirely voluntary. You have the right to withdraw your child from the study at any time, for any reason, without it affecting their future medical care.

Ubicaciones (7)

  • Benioff Children's Hospital
    Código postal verificado
    Oakland, United States
  • University of Minnesota
    Código postal verificado
    Minneapolis, United States
  • Children's Hospital at St. Peter's University Hospital
    Código postal verificado
    New Brunswick, United States
  • The Children's Hospital of Philadelphia
    Código postal verificado
    Filadelfia, Estados Unidos
  • Hospital de Clínicas de Porto Alegre (HCPA)
    Código postal verificado
    Porto Alegre, Brasil
  • Gazi University
    Código postal verificado
    Ankara, Turkey (Türkiye)
  • Hospital Great Ormond Street
    Código postal verificado
    Londres, Reino Unido

Preguntas comunes

What is GM1 gangliosidosis?

It's a rare genetic condition where the body can't break down certain substances, leading to problems, especially in the brain.

What is PBGM01?

It's a new gene therapy treatment being tested. It aims to give the body a working copy of a missing gene to help produce a vital enzyme.

How is PBGM01 given?

It's given as a single injection into an area near the brain.

¿Cuánto tiempo durará el estudio?

The main part of the study will last two years, followed by three more years of safety checks, making a total of five years.

Can we stop participating at any time?

Yes, you can choose to withdraw your child from the study at any point, and it won't affect their regular medical care.

Cómo obtener más información

Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.

Discusión

Discusión comunitaria

Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.